Thirty-day unplanned readmission in hospitalised asthma patients in the USA

2021 ◽  
pp. postgradmedj-2021-140735
Author(s):  
Neel Patel ◽  
Sandeep Singh ◽  
Rupak Desai ◽  
Aakash Desai ◽  
Mohammed Nabeel ◽  
...  

IntroductionHospital quality improvement and hospital performance are commonly evaluated using parameters such as average length of stay (LOS), patient safety measures and rates of hospital readmission. Thirty-day readmission (30-DR) rates are widely used as a quality indicator and a quantifiable metric for hospitals since patients are often readmitted for the exacerbation of conditions from index admission. The quality of patient education and postdischarge care can influence readmission rates. We report the 30-DR rates of patients with asthma using a national dataset for the year 2013.ObjectivesThe aim of our study was to assess the 30- day readmission (30-DR) rate as well as, the causes and predictors of readmissions.Study designs/methodsUsing the Nationwide Readmission Database (NRD) (2013), we identified primary discharge diagnoses of asthma by using International Classification of Diseases, Ninth Revision, Clinical Modification code ‘493’. Categorical and continuous variables were assessed by a χ2 test and a Student’s t-test, respectively. The independent predictors of unplanned 30-DR were detected by multivariate analysis. We used sampling weights, which are provided in the NRD, to generate the national estimates.ResultsThere were 130 490 (weighted N=311 173) inpatient asthma admissions during 2013. The overall 30-DR for asthma was 11.9%. The associated factors for 30-DR were age 45–84 years (40.32% vs 29.05%; p<0.001), enrolment in Medicare (49.33% vs 30.61% p<0.001), extended LOS (mean, 4.40±0.06 vs 3.25±0.04 days; p<0.001), higher mean cost (US$8593.91 vs US$6741.31; p<0.001) and higher disposition against medical advice (DAMA) (4.14% vs 1.51%; p<0.001). The factors that increased the chance of 30-DR were advanced age (≥45–64 vs ≤17 years; OR 4.61, 95% CI 4.04 to 5.27, p<0.0001), male sex (OR 1.19, 95% CI 1.13 to 1.26, p<0.0001), a higher Charlson Comorbidity Index (CCI) (OR 1.16, 95% CI 1.14 to 1.18, p<0.0001), DAMA (OR 2.32, 95% CI 2.08 to 2.59, p<0.0001), non-compliance with medication (OR 1.34, 95% CI 1.24 to 1.46, p<0.0001), post-traumatic stress disorder (OR 1.48, 95% CI 1.22 to 1.79, p<0.0001), alcohol use (OR 1.45, 95% CI 1.27 to 1.65, p<0.0001), gastro-oesophageal reflux disease (OR 1.20, 95% CI 1.14 to 1.27, p<0.0001), obstructive sleep apnoea (OR 1.11, 95% CI 1.03 to 1.18, p<0.0042) and hypertension (OR 1.11, 95% CI 1.06 to 1.17, p<0.0001).ConclusionsWe found that the overall 30-DR rate for asthma was 11.9% all-cause readmission. Major causes of 30-DR were asthma exacerbation (36.74%), chronic obstructive pulmonary disease (11.47%), respiratory failure (6.46%), non-specific pneumonia (6.19%), septicaemia (3.61%) and congestive heart failure (3.32%). One-fourth of the revisits occurred in the first week, while half of the revisits took place in the first 2 weeks. Education regarding illness and the importance of medicine compliance could play a significant role in preventing asthma-related readmission.

Author(s):  
Chantal Simon ◽  
Hazel Everitt ◽  
Françoise van Dorp ◽  
Nazia Hussain ◽  
Emma Nash ◽  
...  

This chapter in the Oxford Handbook of General Practice explores respiratory medicine in general practice. It covers breathlessness, cough, chest signs, and other signs of respiratory disease. It examines asthma in adults, bronchodilators and steroids, asthma management in practice, and drug treatment of asthma, as well as chronic obstructive pulmonary disease (COPD) and acute exacerbations of COPD. It discusses lung cancer, colds and influenza, pneumonia, tuberculosis, cystic fibrosis and Kartagener syndrome, diffuse parenchymal lung disease, occupational lung disease, and snoring and obstructive sleep apnoea.


ESC CardioMed ◽  
2018 ◽  
pp. 2235-2237
Author(s):  
Tauseef Akhtar ◽  
Jared D. Miller ◽  
Hugh Calkins

Rate control, rhythm control, and anticoagulation are well entrenched as the three central pillars of atrial fibrillation (AF) management. Risk factor modification of other associated co-morbidities is now emerging as a critical fourth pillar in the prevention and management of AF. Obstructive sleep apnoea and chronic obstructive pulmonary disease, in particular, have important implications in the development of AF and appropriate selection of therapy. This chapter reviews the pathophysiology and clinical evidence linking these conditions with AF. In addition, it discusses important considerations in the management of concurrent AF and obstructive sleep apnoea or chronic obstructive pulmonary disease.


ESC CardioMed ◽  
2018 ◽  
pp. 2235-2237
Author(s):  
Jared D. Miller ◽  
Hugh G. Calkins

Rate control, rhythm control, and anticoagulation are well entrenched as the three central pillars of atrial fibrillation (AF) management. Risk factor modification of other associated co-morbidities is now emerging as a critical fourth pillar in the prevention and management of AF. Obstructive sleep apnoea and chronic obstructive pulmonary disease, in particular, have important implications in the development of AF and appropriate selection of therapy. This chapter reviews the pathophysiology and clinical evidence linking these conditions with AF. In addition, it discusses important considerations in the management of concurrent AF and obstructive sleep apnoea or chronic obstructive pulmonary disease.


Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Magdi Zordok ◽  
Muhammad Etiwy ◽  
Shruti Hegde ◽  
Michael Maysky

Background: Acute myocardial injury has been reported in approximately 20% of patients with Coronavirus disease 2019 (COVID-19). Little is known about the outcome of this subset of patients. We are testing the hypothesis of higher morbidity and mortality in patients with COVID-19 who have acute myocardial injury. Methods: In this retrospective study, we analyzed data from patients admitted to Steward Healthcare hospitals in Massachusetts between March 22 and April 24, who tested positive for COVID-19 confirmed by serology and found to have elevated troponin levels (>0.01). The sociodemographic information, clinical data, and outcomes of these critically ill patients were retrospectively extracted from the medical records. The primary outcome was in-hospital death. Data were analyzed using JMP statistical analysis software. Results: Two hundred eighty-three COVID-19 positive patients were found to have troponin levels >0.01 on admission. Of these 183 patients (64.6%) were males, 49.1% were Caucasian and 32.1% were African Americans. The mean age of the patients was 70.7 ± 13.8. The prevalence of comorbid conditions was as follows: hypertension, 69.7%; hyperlipidemia, 46.9%; diabetes mellitus, 42.6%; chronic kidney disease, 28.3%; heart failure, 19.3%; atrial fibrillation, 22.1%; coronary artery disease, 17.1%; cerebrovascular accident, 10.2%; obesity, 38%; chronic obstructive pulmonary disease or asthma 20.8%, obstructive sleep apnea, 4.9%. One hundred thirty-seven patients (48.4%) noted to have acute kidney injury on presentation,128 (45.2%) required ICU level of care, 41% required invasive mechanical ventilation for a mean of 10.4 ± 7.9 days, and 38.8% required vasopressors. The average length of stay (LOS) in the medical intensive care unit and the hospital was 11.5 ± 8.3 days and 11.4 ± 9.5 days respectively. The overall in-hospital mortality rate was 45.6%. Conclusion: Patients with COVID-19 and elevated Troponin levels had high morbidity and mortality


2021 ◽  
pp. 163-190
Author(s):  
Sarah Jarvis

This chapter describes the anaesthetic management of the patient with respiratory disease. It describes the assessment of respiratory function and pre-operative respiratory investigations, and ventilatory strategies to reduce pulmonary complications. Common respiratory conditions covered include respiratory tract infection; smoking; asthma; chronic obstructive pulmonary disease; bronchiectasis; cystic fibrosis; obstructive sleep apnoea; sarcoidosis; restrictive pulmonary disease, and the patient with a transplanted lung. For each topic, pre-operative investigation and optimisation, treatment, and anaesthetic management are described. Recommendations for the patient who may require post-operative respiratory support (e.g. non-invasive ventilation) are provided.


Author(s):  
Ian B. Wilkinson ◽  
Tim Raine ◽  
Kate Wiles ◽  
Anna Goodhart ◽  
Catriona Hall ◽  
...  

This chapter explores chest medicine, including respiratory health, bedside tests in chest medicine, further investigations in chest medicine, pneumonia, bronchiectasis, cystic fibrosis (CF), lung tumours, fungi and the lung, asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), respiratory failure, pulmonary embolism (PE), pneumothorax, pleural effusion, obstructive sleep apnoea syndrome, cor pulmonale, sarcoidosis, interstitial lung disease (ILD), extrinsic allergic alveolitis (EAA), idiopathic pulmonary fibrosis (IPF), and industrial dust diseases.


2006 ◽  
Vol 2006 ◽  
pp. 1-5 ◽  
Author(s):  
Christian Schumann ◽  
Kathy Triantafilou ◽  
Stefan Krueger ◽  
Vinzenz Hombach ◽  
Martha Triantafilou ◽  
...  

As a noninvasive method, exhaled breath condensate (EBC) has gained importance to improve monitoring of lung diseases and to detect biomarkers. The aim of the study was to investigate, whether erythropoietin (EPO) is detectable in EBC. EBC was collected from 22 consecutive patients as well as from healthy individuals. Using a multiplex fluorescent bead immunoassay, we detected EPO in EBC, as well as tumour necrosis factor-α(TNF-α) in 13 out of 22 patients simultaneously (EPO 0.21±0.03 in U/mL and TNF-α34.6±4.2 in pg/mL, mean±SEM). No significant differences for EPO levels or correlation between EPO and TNF-αwere found but TNF-αwas significantly higher in patients with chronic obstructive pulmonary disease (COPD) than in non-COPD (obstructive sleep apnoea, OSA, and lung healthy patients). This is the first report of detection of EPO in EBC. Due to the small study size more data is needed to clarify the role of EPO in EBC.


Sign in / Sign up

Export Citation Format

Share Document